In this study, using prior classifications of FOXA1 alterations as our guide (8, 9), we devised a revised classification scheme to stratify patients with prostate cancer based on different types of FOXA1 alterations using a cohort of 5,014 prostate tumors subjected to whole-exome and -transcriptome next-generation sequencing (NGS). This evidence concerns the gene FOXA1 and prostate neoplasm.